These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1195 related items for PubMed ID: 15448019
1. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Kaelin WG. Clin Cancer Res; 2004 Sep 15; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019 [Abstract] [Full Text] [Related]
2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER. Cancer Res; 2002 Jul 01; 62(13):3803-11. PubMed ID: 12097293 [Abstract] [Full Text] [Related]
3. Role of VHL gene mutation in human cancer. Kim WY, Kaelin WG. J Clin Oncol; 2004 Dec 15; 22(24):4991-5004. PubMed ID: 15611513 [Abstract] [Full Text] [Related]
4. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Oncogene; 2000 Nov 16; 19(48):5435-43. PubMed ID: 11114720 [Abstract] [Full Text] [Related]
6. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG. Hum Mol Genet; 2001 May 01; 10(10):1019-27. PubMed ID: 11331612 [Abstract] [Full Text] [Related]
7. Identification of novel VHL target genes and relationship to hypoxic response pathways. Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Richards FM, Johnson CM, Maher ER. Oncogene; 2005 Jun 30; 24(28):4549-58. PubMed ID: 15824735 [Abstract] [Full Text] [Related]
8. The von Hippel-Lindau tumor suppressor gene. Kondo K, Kaelin WG. Exp Cell Res; 2001 Mar 10; 264(1):117-25. PubMed ID: 11237528 [Abstract] [Full Text] [Related]
14. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. Na X, Wu G, Ryan CK, Schoen SR, di'Santagnese PA, Messing EM. J Urol; 2003 Aug 10; 170(2 Pt 1):588-92. PubMed ID: 12853836 [Abstract] [Full Text] [Related]
15. A variety of phenotype with R161Q germline mutation of the von Hippel-Lindau tumor suppressor gene in Japanese kindred. Iida K, Okimura Y, Takahashi K, Inomata S, Iguchi G, Kaji H, Chihara K. Int J Mol Med; 2004 Mar 10; 13(3):401-4. PubMed ID: 14767570 [Abstract] [Full Text] [Related]
16. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cuevas Y, Hernández-Alcoceba R, Aragones J, Naranjo-Suárez S, Castellanos MC, Esteban MA, Martín-Puig S, Landazuri MO, del Peso L. Cancer Res; 2003 Oct 15; 63(20):6877-84. PubMed ID: 14583486 [Abstract] [Full Text] [Related]
18. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. Kaelin WG. Cold Spring Harb Symp Quant Biol; 2005 Oct 15; 70():159-66. PubMed ID: 16869749 [Abstract] [Full Text] [Related]
20. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Baba M, Hirai S, Yamada-Okabe H, Hamada K, Tabuchi H, Kobayashi K, Kondo K, Yoshida M, Yamashita A, Kishida T, Nakaigawa N, Nagashima Y, Kubota Y, Yao M, Ohno S. Oncogene; 2003 May 08; 22(18):2728-38. PubMed ID: 12743597 [Abstract] [Full Text] [Related] Page: [Next] [New Search]